NicOx partners with Bausch & Lomb for its candidate glaucoma drug

Article

A worldwide licensing deal has been made between NicOx, the French biotech business and Bausch & Lomb for the former's candidate glaucoma drug NCX 116.

A worldwide licensing deal has been made between NicOx, the French biotech business and Bausch & Lomb for the former's candidate glaucoma drug NCX 116.

B&L will also be able to consider development and marketing of other products containing NCX 116 under the terms of the agreement. Phase II trials have been completed and clinical trials in patients with glaucoma and ocular hypertension are underway.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Subscribe Now!
Recent Videos
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
Related Content
A person stands in front of a white screen, facing an audience. The speaker and audience are visible in silhouette. Concept image for European Society of Retina Specialists (EURETINA) clinical trial data presentation. Logos courtesy of EURETINA, Ashvattha Therapeutics, Clearside Biomedical and Carl Zeiss Medical Technology. Background image courtesy of TezcanKemal, Getty Images. Created with Canva.

Ashvattha Therapeutics, Clearside Biomedical, ZEISS preview EURETINA presentations

Kassi Filkins
August 30th 2025
Article
Higher molar dose and its translation into clinical practice. Led by John Kitchens, MD; Joined by Peter Kaiser, MD

Higher Molar Dose and Its Translation into Clinical Practice

John Kitchens, MD;Peter Kaiser, MD
August 30th 2025
Podcast
A person speaks on a stage during a conference/lecture. Concept image for 2025 EURETINA European Society of Retina specialists scientific meeting. Image credit: ©Anton Gvozdikov – stock.adobe.com

The Eye Care Network's clinical advisors will present at EURETINA

Hattie Hayes
August 30th 2025
Article
The Eiffel Tower/La Tour Eiffel, as viewed from under a bridge in Paris, France. Concept image for EURETINA 25th anniversary and retina specialist meeting conference in Europe. Image credit: ©Dario – stock.adobe.com

What to expect at this year's European Society of Retina Specialists (EURETINA) Congress

Hattie Hayes
August 30th 2025
Article
Concept image for the balancing of energy efficiency and time in refractive surgery phacoemulsification. A scale, with a laser beam of blue light on one side, and an analog alarm clock on the other side. The laser beam of blue light is surrounded by static. Created with Canva Magic AI.

Keys to optimising phaco efficiency

Marta Ibarz, MD, PhD
August 30th 2025
Article
European Union flags outside the Berlaymont building in Brussels, Belgium, the headquarters of the European Commission. Concept image for ZEISS Medical Technology CE Mark CIRRUS PathFinder AI. Image credit: © olrat – stock.adobe.com

European Commission issues CE mark for Zeiss CIRRUS PathFinder AI tool

Hattie Hayes
August 30th 2025
Article
© 2025 MJH Life Sciences

All rights reserved.